5 things to know about the new Alzheimer's drug — including why it may be risky for people who take blood thinnersMarket Watch • 11/30/22
Biogen stock up 3% premarket after update on Alzheimer's treatment; Stifel reiterates buy ratingMarket Watch • 11/30/22
Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen InvestorsInvestors Business Daily • 11/30/22
New Alzheimer's drug slows decline in memory - fuelling hope doctors will one day cure dementiaSkynews • 11/30/22
Eisai, Biogen Alzheimer's drug slows cognitive decline, safety for some becomes focusReuters • 11/30/22
ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGLAND JOURNAL OF MEDICINEPRNewsWire • 11/30/22
EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCEPRNewsWire • 11/30/22
Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study SuccessInvestors Business Daily • 11/28/22
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for ZuranoloneBusiness Wire • 11/22/22
CONTINUED INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Continues to Investigate Biogen Inc.'s Directors and Officers for Breach of Fiduciary Duties – BIIBBusiness Wire • 11/17/22
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The HelmInvestors Business Daily • 11/16/22